CNW Stock Overview
co.don AG, a biopharmaceutical company, develops, produces, and markets biopharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
co.don AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.013 |
| 52 Week High | €0.052 |
| 52 Week Low | €0.0078 |
| Beta | 0 |
| 1 Month Change | -0.79% |
| 3 Month Change | -49.19% |
| 1 Year Change | -56.90% |
| 3 Year Change | -99.25% |
| 5 Year Change | -99.87% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| CNW | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -2.0% |
| 1Y | -56.9% | -21.1% | -0.3% |
Return vs Industry: CNW underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: CNW underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| CNW volatility | |
|---|---|
| CNW Average Weekly Movement | 35.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CNW's share price has been volatile over the past 3 months.
Volatility Over Time: CNW's weekly volatility has decreased from 55% to 35% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | Xing Zhao | www.codon.de |
co.don AG, a biopharmaceutical company, develops, produces, and markets biopharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three-dimensional cartilage cell transplant product that is used to treat cartilage defects in adult knee joints and adolescents; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, and shoulder and elbow. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.
co.don AG Fundamentals Summary
| CNW fundamental statistics | |
|---|---|
| Market cap | €334.04k |
| Earnings (TTM) | -€14.12m |
| Revenue (TTM) | €9.84m |
0.0x
P/S Ratio0.0x
P/E RatioIs CNW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNW income statement (TTM) | |
|---|---|
| Revenue | €9.84m |
| Cost of Revenue | €1.88m |
| Gross Profit | €7.96m |
| Other Expenses | €22.09m |
| Earnings | -€14.12m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CNW perform over the long term?
See historical performance and comparison